Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy

DISEASE CHARACTERISTICS:

Histologically confirmed recurrent adenocarcinoma of the prostate within the past year

No transitional cell, small cell, or squamous cell carcinoma of the prostate
Local recurrence

Disease recurred ≥ 18 months after completion of prior external beam radiotherapy (EBRT) for stage T1-T2b, N0/X, M0 disease

Biochemical failure as defined by the Phoenix definition (rise in PSA by 2 ng/mL or more above the nadir PSA)

PSA ≥ 0.3 ng/mL to < 20 ng/mL measured within the past 30 days
Pre-EBRT PSA < 50 ng/mL
Prior locally recurrent hormone-refractory disease allowed
American Urologic Association Obstructive Symptom Index Score ≤ 24
No known standard therapy that is potentially curative or definitely capable of extending life expectancy

No evidence of or history of metastatic adenocarcinoma of the prostate

Negative radiographic metastatic work-up including whole-body radionuclide bone scan, CT and/or MR scan of the pelvis and abdomen, and chest x-ray

Patients with suspicious areas on conventional imaging studies are eligible provided they are biopsy negative
No known CNS metastases
No prostate size > 140 cc

PATIENT CHARACTERISTICS:

ECOG performance status 0-2
Life expectancy ≥ 12 weeks
ANC ≥ 1,500/μL
Platelet count ≥ 100,000/μL
Hemoglobin ≥ 8.5 g/dL
Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
INR ≤ 1.4 times ULN
Creatinine ≤ 1.5 times ULN
Thyroid-stimulating hormone 0.3-5.0 uIU/mL and free thyroxine 0.8-1.87 ng/dL
Willing to provide biologic specimens and participate in imaging studies as required

Willing to maintain a low-iodine diet for 12 days

Starting 7 days prior to study virus injection continuing until after the iodine I 131 radioiodine therapy on day 5

No more than 1 of the following renal/genitourinary toxicities:

Bladder spasms
Dysuria (painful urination)
Genitourinary fistula
Hemoglobinuria
Incontinence
Operative injury to bladder and/or ureter
Proteinuria
Renal failure
Uretal obstruction
Urinary frequency/urgency
Urinary retention
Urine color change (not related to other dietary or physiologic cause [e.g., bilirubin, concentrated urine, or hematuria])
Other renal/genitourinary toxicities
No urinary tract infection within 72 hours prior to registration
No pubic arch interference study demonstrating unacceptable prostate access by the transperineal approach
No absence of rectum or other anatomic features that would preclude transperineal needle insertion into the prostate
No coagulopathy that contraindicates transperineal and intraprostatic needle insertion
No other cancer within the past 2 years, except for squamous cell and basal cell skin cancers
No uncontrolled infection or fever > 100°F
No known cardiac disease
No seizure disorder
No documented history of HIV positivity or other acquired immunodeficiency disorder or congenital immunodeficiency disorder

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
Recovered from acute, reversible effects of prior chemotherapy

Androgen-deprivation therapy (if applicable) initiated more than 3 months prior to registration

Patients who have undergone bilateral orchiectomy are eligible if they meet all other criteria
At least 6 weeks since prior bicalutamide, nilutamide, or oral or intravenous iodinated contrast
At least 4 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas), immunotherapy, biologic therapy, or other experimental drugs
At least 4 weeks since prior and no concurrent anti-androgens (e.g., flutamide, estrogens, ketoconazole, PC-SPES, finasteride, or megestrol acetate)

At least 2 weeks since prior and no concurrent exogenous corticosteroids

Patients clinically proven to require maintenance steroids allowed provided there has been no change in their dose within the past 6 weeks
No antibiotic therapy within the past 72 hours
No prior organ transplantation
No prior salvage prostatectomy or brachytherapy
No other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational
No concurrent prophylactic use of colony-stimulating factors
No concurrent enrollment in any other study involving a pharmacologic agent (drugs, biologics, immunotherapy approaches, gene therapy) whether for symptom control or therapeutic intent